More ear­ly da­ta ma­nip­u­la­tion is­sues tied to No­var­tis block­buster as Na­ture re­tracts pa­per

No­var­tis’ block­buster gene ther­a­py Zol­gens­ma has proven to be a ma­jor suc­cess sto­ry as a spinal mus­cu­lar at­ro­phy treat­ment, help­ing chil­dren who might not oth­er­wise be able to stand or walk due to the rare con­di­tion.

But last week, the jour­nal Na­ture Biotech­nol­o­gy sur­faced a new flaw in the ther­a­py’s ear­li­est phase of de­vel­op­ment, and de­spite the au­thors’ ob­jec­tions, the jour­nal re­tract­ed an ar­ti­cle from Feb­ru­ary 2010 not­ing “mul­ti­ple in­ac­cu­ra­cies in the re­port­ed mouse lifes­pans and in the an­i­mal in­clu­sions and ex­clu­sions.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.